Alto Neuroscience posts Q3 2025 results update

Alto Neuroscience, Inc. filed a Form 8-K stating that it reported financial results for the fiscal quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/12/2025 - 08:02 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Alto Neuroscience, Inc. filed a Form 8-K stating that it reported financial results for the fiscal quarter ended September 30, 2025. The company released these quarterly results in a press release dated November 12, 2025, which is furnished as Exhibit 99.1 and incorporated by reference.

The Form 8-K clarifies that the financial information, including the press release, is being furnished rather than filed under the Exchange Act and is not subject to certain liability provisions, unless specifically incorporated into other SEC filings.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alto Neuroscience (ANRO) disclose in this Form 8-K?

Alto Neuroscience filed a Form 8-K to disclose that it reported financial results for its fiscal quarter ended September 30, 2025, via a press release furnished as Exhibit 99.1 and incorporated by reference.

Which period do Alto Neuroscience (ANRO) results in this 8-K cover?

The Form 8-K states that Alto Neuroscience reported financial results for the fiscal quarter ended September 30, 2025. These results are detailed in a press release dated November 12, 2025, attached as Exhibit 99.1.

How were Alto Neuroscience (ANRO) Q3 2025 results provided to investors?

Alto Neuroscience provided its quarter ended September 30, 2025 financial results through a press release dated November 12, 2025. This press release is furnished as Exhibit 99.1 to the Form 8-K and incorporated by reference.

Is the Alto Neuroscience (ANRO) earnings press release deemed filed with the SEC?

The Form 8-K specifies that the information in Item 2.02, including the Exhibit 99.1 press release, is being furnished and not deemed filed under Section 18 of the Exchange Act, unless expressly incorporated by reference in another filing.

What exhibits are attached to Alto Neuroscience (ANRO) Form 8-K?

The Form 8-K lists two exhibits: Exhibit 99.1, which is the Alto Neuroscience press release detailing quarterly results, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001999480False00019994802025-11-122025-11-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 12, 2025

_____________________

ALTO NEUROSCIENCE, INC.

(Exact Name of Registrant as Specified in its Charter)

_____________________

Delaware

001-41944

83-4210124

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

650 Castro Street, Suite 450, Mountain View, CA			94041
(Address of principal executive offices)			(Zip Code)

Registrant’s telephone number, including area code: (650) 200-0412

N/A

(Former name or former address, if changed since last report)

_____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

ANRO

New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On November 12, 2025, Alto Neuroscience, Inc. (the “Company”) reported financial results for the fiscal quarter ended September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K (the "Current Report") and is incorporated by reference herein.

The information in this Item 2.02 of this Current Report (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)Exhibits.

Exhibit No.						Description
99.1						Press Release of Alto Neuroscience, Inc.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			ALTO NEUROSCIENCE, INC.
Dated: November 12, 2025			By:			/s/ Amit Etkin
						Amit Etkin, M.D., Ph.D.
						President and Chief Executive Officer